Cell & Gene Therapy Supply Chain Software Market Expected to Grow at a 13.9% CAGR from 2024-2031 | Latest Report by InsightAce Analytic

PR Newswire
Monday, June 10, 2024 at 2:15pm UTC

Cell & Gene Therapy Supply Chain Software Market Expected to Grow at a 13.9% CAGR from 2024-2031 | Latest Report by InsightAce Analytic

PR Newswire

JERSEY CITY, N.J., June 10, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell & Gene Therapy Supply Chain Software Market Size, Share & Trends Analysis Report By Business Type (Transport, Warehouse, Distribution, Value-Added Services), Mode Of Operation (Storage, Roadways, Seaways), And End Use, Region, Market Outlook And Industry Analysis 2031".

InsightAce Analytic Pvt. Ltd Logo

The Cell & Gene Therapy Supply Chain Software Market is poised for significant growth, projected to surpass USD 668.4 Mn by 2031, with a promising CAGR of 13.9% during the forecast period.

Enhanced therapies, including cell and gene therapy products, have reformed healthcare practices. The prevalence of such therapeutic options has led to an uprise shift in modern medicine's development, production, and consumption. Moreover, such therapies have established healthcare providers to treat several rare clinical conditions.

Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/2520 

Supply chain software in this sector encompasses solutions for inventory management, logistics, temperature monitoring, and regulatory compliance. It facilitates the coordination of multiple stakeholders, including manufacturers, contract research organizations (CROs), logistics providers, and healthcare facilities. Investments in R&D are also essential for advancing technological innovations and raising the caliber of produced goods.

Furthermore, the market's future potential appears bright because of the growing use of digitalization. Various software solutions play crucial roles in these processes, including cell rearrangement platforms, Enterprise-manufacturing systems, inventory management systems, laboratory information management systems, logistics management systems, patient management systems, quality management systems, and tracking and tracing systems.

List of Prominent Key Players in the Cell and Gene Therapy Supply Chain Software Market:

  • Azenta Life Sciences
  • Biocair
  • BioLife Solutions
  • CareDx
  • Cryoport
  • Lonza
  • NMDP BioTherapies
  • TraceLink
  • TrakCel
  • Veeva Systems
  • Emerson
  • LabVantage Solutions
  • Marken
  • MasterControl
  • QuickSTAT
  • Siemens
  • Stafa Cellular Therapy
  • Steiner
  • STEMSOFT Software
  • TECHNICAL
  • Thermo Fisher Scientific
  • Other Prominent Players

Cell and Gene Therapy Supply Chain Software Market Scope:

Report Attribute

Specifications

Market Size Value In 2023

USD 240.5 Mn

Revenue Forecast In 2031

USD 668.4 Mn

Growth Rate CAGR

CAGR of 13.9% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Mn, and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Process Component, Type of Software, Mode of Deployment, Type of End-User, And Scale of Operation

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea

Order 180 Pages Full Report @  https://www.insightaceanalytic.com/buy-report/2520 

Market Dynamics:

Drivers-

Several key factors drive the Cell and Gene Therapy Supply Chain Software Market. Primarily, the rising demand for personalized medicine and advanced therapies fuels the need for efficient supply chain management solutions. Also, the complexity of cell and gene therapy manufacturing requires sophisticated software to ensure product quality and compliance with regulatory standards. In addition, the rising number of clinical trials and commercial launches of these therapies boosts demand for software that can accommodate the unique challenges of their supply chains. Lastly, the COVID-19 pandemic has underscored the importance of resilient supply chains, driving further interest in software solutions to enhance agility and visibility.

Challenges:

The Cell & Gene Therapy Supply Chain Software Market faces several challenges. The high cost of developing and implementing specialized software poses a barrier to entry for smaller companies. Also, regulatory complexities and stringent compliance requirements add layers of difficulty to software development and usage. Interoperability issues between different systems can hinder seamless data exchange and integration. Lastly, the need for continuous adaptation to evolving technologies and industry standards presents ongoing challenges for software providers and users alike, requiring constant updates and enhancements to meet the dynamic needs of the cell and gene therapy sector.

Regional Trends:

North America is a leading region in the biotechnology and pharmaceutical industries, boasting a robust ecosystem of companies specializing in cell and gene therapy research, development, and manufacturing. The region's leading software companies and technology hubs further enhance its position. This comprehensive overview of regional trends is crucial for regulatory authorities to stay informed and make informed decisions.

Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/2520 

Recent Developments:

  • In January 2024, Veeva Systems partnered with SK Biopharmaceuticals to optimize the former company's quality management system and decrease the risks involved with quality assurance of regenerative healthcare medicine.
  • In Nov 2023, Cryoport, Inc. announced its acquisition of Tec4med LifeScience GmbH. Cryoport's acquire of Tec4med is a significant step in broadening their range of condition monitoring solutions, fostering new product development, and accelerating European market penetration, notably in the DACH area (Germany, Austria, Switzerland).
  • In June 2023, Biocair has integrated TrakCel's software with OCELLOS to increase customer service, automation, and visibility in the cell and gene therapy (CGT) supply chain.TrakCel's advanced therapeutic orchestration platform OCELLOS streamlines the cell, gene, and immunotherapy supply chain. To scale cell and gene therapy development, the platform tracks chain of identification and custody. This lets stakeholders track orders in transit.

Segments of Cell and Gene Therapy Supply Chain Software Market -

By Process Component-              

  • Sample Collection and Processing Component
  • Manufacturing Component
  • Logistics Component
  • Patient Identification and Treatment Follow-up Component

By Type of Software-    

  • Enterprise Manufacturing System (EMS)
  • Laboratory Information Management System (LIMS)
  • Inventory Management System (IMS)
  • Cell Orchestration Platform (COP)
  • Quality Management System (QMS)
  • Logistics Management System (LMS)
  • Patient Management System (PMS)

By Mode of Deployment-           

  • On-premises Deployment
  • Cloud-based Deployment

By Type of End-User-    

  • Pharmaceutical Companies
  • Cell Therapy Labs
  • Hospitals / Medical Centers
  • Research Institutes / Biobanks

By Scale of Operation- 

  • Clinical Scale
  • Commercial Scale

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/2520 

Why should buy this report:

  • To receive a comprehensive analysis of the prospects for global Cell and Gene Therapy Supply Chain Software market
  • To receive industry overview and future trends of global Cell and Gene Therapy Supply Chain Software market
  • To analyze the Cell and Gene Therapy Supply Chain Software market drivers and challenges
  • To get information on the Cell and Gene Therapy Supply Chain Software market size value (US$ Mn) forecast till 2031
  • Major Investments, Mergers & Acquisition in global Cell and Gene Therapy Supply Chain Software industry

Other Related Reports Published by InsightAce Analytic:

AI in Patient Management Market 

Digital Pharmaceutical Supply Chain Management Market 

4PL Logistics Market

AI in Medical Supplies/Inventory Management Market

Patient Engagement Solutions Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:
InsightAce Analytic PVT. LTD
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Follow us on LinkedIn: https://www.linkedin.com/company/insightace-analytic-pvt-ltd/

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

 

Cision View original content:https://www.prnewswire.com/news-releases/cell--gene-therapy-supply-chain-software-market-expected-to-grow-at-a-13-9-cagr-from-2024-2031--latest-report-by-insightace-analytic-302168218.html

SOURCE InsightAce Analytic Pvt. Ltd